Evidence map›Paper›PMID 38319243›Full record

ArticleAnalytical chemistry2024

Characterization of Large Immune Complexes with Size Exclusion Chromatography and Native Mass Spectrometry Supplemented with Gas Phase Ion Chemistry.

Yang Yang, Daniil G Ivanov, Michael D Levin, Bogdan Olenyuk, Oscar Cordova-Robles, Brittany Cederstrom, Jan E Schnitzer, Igor A Kaltashov

Abstract read
In one paragraph

Article in Analytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. AsymmetricJournal of the American Chemical Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yang YangDepartment of Chemistry, University of Massachusetts-Amherst, Amherst, Massachusetts 01003, USA.
Daniil G IvanovDepartment of Chemistry, University of Massachusetts-Amherst, Amherst, Massachusetts 01003, USA.ORCID 0000-0003-2987-1048
Michael D LevinProteogenomics Research Institute for Systems Medicine, La Jolla, California 92037, USA.
Bogdan OlenyukProteogenomics Research Institute for Systems Medicine, La Jolla, California 92037, USA.
Oscar Cordova-RoblesProteogenomics Research Institute for Systems Medicine, La Jolla, California 92037, USA.
Brittany CederstromProteogenomics Research Institute for Systems Medicine, La Jolla, California 92037, USA.
Jan E SchnitzerProteogenomics Research Institute for Systems Medicine, La Jolla, California 92037, USA.
Igor A KaltashovDepartment of Chemistry, University of Massachusetts-Amherst, Amherst, Massachusetts 01003, USA.ORCID 0000-0002-4355-6039
Proteogenomics Research Institute for Systems Medicine · USUniversity of Massachusetts Amherst · US

Funding

ZDS2P REGULATES SWE1P-DEPENDENT POLARIZED CELL GROWTH IN S CEREVISIAEP41RR011823 · NCRR · UNIVERSITY OF WASHINGTON · PI DAVIS, TRISHA N. · 1996 to 2011
$24.7M
Targeting TGF-b Inhibitors and PPAR-y Agonists To Enhance IPF TherapyP01HL119165 · NHLBI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI SCHNITZER, JAN EUGENIUSZ · 2015 to 2019
$13.6M
Tumor Imaging CoreP01CA221775 · NCI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI LI, YUFENG · 2019 to 2023
$13.2M
Mapping Vascular Proteome for Organ Targeting in VivoR01HL074063 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TALAMINI, MARK A · 2005 to 2009
$3.8M
Bispecific immunotherapeutic delivery system for lung diseasesR01HL169760 · NHLBI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI Jan Eugeniusz Schnitzer · 2023 to 2026
$3.7M
Proteomic Resource for Basic &Clinical Cancer ResearchR24CA095893 · NCI · SIDNEY KIMMEL CANCER CENTER · PI SCHNITZER, JAN EUGENIUSZ · 2002 to 2006
$1.9M
Cross-path reactive chromatography/mass spectrometry as a versatile platform for characterization of primary and higher order structure of complex heterogeneous proteinsR01GM132673 · NIGMS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI KALTASHOV, IGOR A · 2019 to 2022
$1.2M
NCI NIH HHS P01 CA221775NCI NIH HHS R24 CA095893NCRR NIH HHS P41 RR011823NHLBI NIH HHS P01 HL119165NHLBI NIH HHS R01 HL074063NHLBI NIH HHS R01 HL169760NIGMS NIH HHS R01 GM132673
6 · The paper itself

Abstract

Large immune complexes formed by the cross-linking of antibodies with polyvalent antigens play critical roles in modulating cell-mediated immunity. While both the size and the shape of immune complexes are important determinants in Fc receptor-mediated signaling responsible for phagocytosis, degranulation, and, in some instances, autoimmune pathologies, their characterization remains extremely challenging due to their large size and structural heterogeneity. We use native mass spectrometry (MS) supplemented with limited charge reduction in the gas phase to determine the stoichiometry of immune complexes formed by a bivalent (homodimeric) antigen, a 163 kDa aminopeptidase P2 (APP2), and a monoclonal antibody (mAb) to APP2. The observed (APP2·mAb)

Identifiers

PMID38319243
PMCPMC13264487
OpenAlexW4391563785

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.